Type I PRMT inhibitors, which mainly target the predominant PRMT1 in vivo, induce cell death and arrest proliferation in leukemia and lymphoma cell lines and reduce their ability to form tumors in xenotransplantation models (Fedoriw et al., 2019; Fong et al., 2019). The gene discussed is PRMT1; the disease is lymphoma.